Loading
The third BRAF-MEK combination, encorafenib plus binimetinib, delayed progression more than vemurafenib and produced the longest median survival of any targeted regimen in BRAF-mutant melanoma, with less fever than dabrafenib-trametinib.
Phase 3 trial of 577 patients with advanced BRAF V600-mutant melanoma randomised to encorafenib plus binimetinib, encorafenib alone or vemurafenib alone.
Median progression-free survival was 14.9 months with the combination against 7.3 months with vemurafenib (hazard ratio 0.54), and median overall survival 33.6 versus 16.9 months on later analysis; the combination had a distinct toxicity profile with less pyrexia and photosensitivity.
Encorafenib-binimetinib is one of three standard BRAF-MEK doublets for advanced melanoma and is often chosen for its tolerability.
Shares COLUMBUS, The Lancet Oncology.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
Shares COLUMBUS, Encorafenib, BRAF V600-mutant melanoma.
Shares Binimetinib, Encorafenib.
Shares Vemurafenib, BRAF V600-mutant melanoma.
Shares Binimetinib, Encorafenib.
Shares Binimetinib, Encorafenib.